IFP Advisors’s Nuvectis Pharma NVCT Stock Holding History

IFP Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.69K	Sell	80 -10	-11%	-$211	﹤0.01%	4300
2026 Q2	$1.66K	Buy	+90	New	+$1.01K	﹤0.01%	4317

Other funds holding NVCT

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

IFP Advisors's NVCT Position: Q3 2026 in Review

IFP Advisors reduced its Nuvectis Pharma (NVCT) stake by 11% in Q3 2026, selling an estimated $211 and leaving 80 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4300.

IFP Advisors first reported a position in NVCT in Q2 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

IFP Advisors held 80 shares of Nuvectis Pharma worth $1.69K as of Q3 2026.
IFP Advisors sold 10 Nuvectis Pharma shares in Q3 2026, an estimated $211.
Nuvectis Pharma made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4300 holding.
IFP Advisors first reported a position in Nuvectis Pharma in Q2 2026 and has held it in 2 quarters since.
9 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.